학술논문
Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers
Document Type
article
Author
Nasim Mavaddat; Antonis C. Antoniou; Thea M. Mooij; Maartje J. Hooning; Bernadette A. Heemskerk-Gerritsen; GENEPSO; Catherine Noguès; Marion Gauthier-Villars; Olivier Caron; Paul Gesta; Pascal Pujol; Alain Lortholary; EMBRACE; Daniel Barrowdale; Debra Frost; D. Gareth Evans; Louise Izatt; Julian Adlard; Ros Eeles; Carole Brewer; Marc Tischkowitz; Alex Henderson; Jackie Cook; Diana Eccles; HEBON; Klaartje van Engelen; Marian J. E. Mourits; Margreet G. E. M. Ausems; Linetta B. Koppert; John L. Hopper; Esther M. John; Wendy K. Chung; Irene L. Andrulis; Mary B. Daly; Saundra S. Buys; kConFab Investigators; Javier Benitez; Trinidad Caldes; Anna Jakubowska; Jacques Simard; Christian F. Singer; Yen Tan; Edith Olah; Marie Navratilova; Lenka Foretova; Anne-Marie Gerdes; Marie-José Roos-Blom; Flora E. Van Leeuwen; Brita Arver; Håkan Olsson; Rita K. Schmutzler; Christoph Engel; Karin Kast; Kelly-Anne Phillips; Mary Beth Terry; Roger L. Milne; David E. Goldgar; Matti A. Rookus; Nadine Andrieu; Douglas F. Easton; on behalf of IBCCS; kConFab; BCFR
Source
Breast Cancer Research, Vol 22, Iss 1, Pp 1-11 (2020)
Subject
Language
English
ISSN
1465-542X
Abstract
Abstract Background The effect of risk-reducing salpingo-oophorectomy (RRSO) on breast cancer risk for BRCA1 and BRCA2 mutation carriers is uncertain. Retrospective analyses have suggested a protective effect but may be substantially biased. Prospective studies have had limited power, particularly for BRCA2 mutation carriers. Further, previous studies have not considered the effect of RRSO in the context of natural menopause. Methods A multi-centre prospective cohort of 2272 BRCA1 and 1605 BRCA2 mutation carriers was followed for a mean of 5.4 and 4.9 years, respectively; 426 women developed incident breast cancer. RRSO was modelled as a time-dependent covariate in Cox regression, and its effect assessed in premenopausal and postmenopausal women. Results There was no association between RRSO and breast cancer for BRCA1 (HR = 1.23; 95% CI 0.94–1.61) or BRCA2 (HR = 0.88; 95% CI 0.62–1.24) mutation carriers. For BRCA2 mutation carriers, HRs were 0.68 (95% CI 0.40–1.15) and 1.07 (95% CI 0.69–1.64) for RRSO carried out before or after age 45 years, respectively. The HR for BRCA2 mutation carriers decreased with increasing time since RRSO (HR = 0.51; 95% CI 0.26–0.99 for 5 years or longer after RRSO). Estimates for premenopausal women were similar. Conclusion We found no evidence that RRSO reduces breast cancer risk for BRCA1 mutation carriers. A potentially beneficial effect for BRCA2 mutation carriers was observed, particularly after 5 years following RRSO. These results may inform counselling and management of carriers with respect to RRSO.